Related Experiment Video
Updated: Jun 6, 2026
Isolation of CD133+ Liver Stem Cells for Clonal Expansion
Published on: October 10, 2011
Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease
Hosny Salama1, Abdel-Rahman N Zekri, Abeer A Bahnassy
1Tropical Medicine Department, El-Kasr Al-Aini School of Medicine, Kasr Al-Aini st., Kasr Al-Aini, 11977 Cairo, Egypt.
Insights
Autologous stem cell infusion using CD34(+) and CD133(+) cells shows promise for end-stage liver disease. This supportive therapy improved liver enzymes and function in over half of treated patients with good tolerability.
Area of Science:
- Regenerative Medicine
- Hepatology
- Stem Cell Therapy
Background:
- End-stage liver disease (ESLD) presents a significant therapeutic challenge.
- Current treatments for ESLD are limited and often involve transplantation.
- Exploring novel regenerative approaches is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of autologous CD34(+) and CD133(+) stem cell infusion in patients with ESLD.
- To assess the safety and tolerability of this stem cell therapy.
- To determine if stem cell infusion can serve as a supportive treatment modality.
Main Methods:
- A randomized controlled trial involving 140 patients with ESLD.
- Group 1 (n=90): Received granulocyte colony-stimulating factor followed by autologous CD34(+) and CD133(+) stem cell infusion into the portal vein.
- Group 2 (n=50): Received standard liver treatment as a control group.
Main Results:
- 54.5% of patients in the stem cell group showed near normalization of liver enzymes and improved synthetic function.
- 13.6% of the infused group experienced stable disease.
- No improvement was observed in the control group, and no adverse effects were reported.
Conclusions:
- Autologous CD34(+) and CD133(+) stem cell infusion is a well-tolerated supportive therapy for ESLD.
- This approach demonstrates potential for improving liver function in patients with advanced liver disease.
- Further research may validate stem cell therapy as a viable option for ESLD management.
Aim:
To assess the utility of an autologous CD34(+) and CD133(+) stem cells infusion as a possible therapeutic modality in patients with end-stage liver diseases.
Methods:
One hundred and forty patients with end-stage liver diseases were randomized into two groups. Group 1, comprising 90 patients, received granulocyte colony stimulating factor for five days followed by autologous CD34(+) and CD133(+) stem cell infusion in the portal vein. Group 2, comprising 50 patients, received regular liver treatment only and served as a control group.
Results:
Near normalization of liver enzymes and improvement in synthetic function were observed in 54.5% of the group 1 patients; 13.6% of the patients showed stable states in the infused group. None of the patients in the control group showed improvement. No adverse effects were noted.
Conclusion:
Our data showed that a CD34(+) and CD133(+) stem cells infusion can be used as supportive treatment for end-stage liver disease with satisfactory tolerability.
More Related Videos
11:37Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
Published on: June 18, 2018
08:52Isolation and Enrichment of Liver Progenitor Subsets Identified by a Novel Surface Marker Combination
Published on: February 18, 2017
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...